Analysts Set Fulgent Genetics, Inc. (NASDAQ:FLGT) Target Price at $32.00

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have been assigned a consensus rating of “Hold” from the five research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $32.00.

Several brokerages recently issued reports on FLGT. Zacks Research downgraded shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th.

Hedge Funds Weigh In On Fulgent Genetics

Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. raised its stake in Fulgent Genetics by 2,984,354.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after purchasing an additional 1,522,021 shares during the period. RTW Investments LP purchased a new stake in shares of Fulgent Genetics during the 4th quarter valued at $18,521,000. JPMorgan Chase & Co. grew its stake in shares of Fulgent Genetics by 767.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after buying an additional 264,524 shares during the period. Diametric Capital LP acquired a new stake in shares of Fulgent Genetics during the 2nd quarter worth $3,359,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Fulgent Genetics by 89.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 348,533 shares of the company’s stock worth $9,156,000 after buying an additional 164,535 shares during the period. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Stock Up 1.7%

FLGT opened at $15.90 on Friday. The firm has a market cap of $496.56 million, a P/E ratio of -8.11 and a beta of 0.94. The business’s fifty day simple moving average is $20.35 and its 200 day simple moving average is $23.84. Fulgent Genetics has a 52 week low of $13.46 and a 52 week high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.14. The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, equities analysts expect that Fulgent Genetics will post -0.85 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.